Treatment sequencing and impact of number of treatment lines on survival in follicular lymphoma: A national population-based study
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Many follicular lymphoma (FL) patients can be managed with watch-and-wait (WaW). However, those requiring multiple treatment lines face significant unmet needs, highlighting the importance of real-world data for FL management.
Area Of Science
- Hematology
- Oncology
- Clinical Epidemiology
Background
- Follicular lymphoma (FL) is a heterogeneous non-Hodgkin lymphoma.
- Treatment patterns and survival outcomes in a real-world population setting are not well-defined.
Purpose Of The Study
- To describe treatment sequencing, number of lines of therapy, and survival in a population-based cohort of follicular lymphoma patients.
- To identify clinical unmet needs in follicular lymphoma management.
Main Methods
- Retrospective analysis of the Swedish Lymphoma Register (2007-2014 diagnoses, followed until 2020).
- Inclusion of data on progression, transformation, and subsequent lines of therapy.
- Kaplan-Meier estimates and cumulative incidence were used for survival and transformation analysis.
Main Results
- Among 1792 FL patients, 69% received first-line systemic treatment, 20% underwent watch-and-wait (WaW), and 10% received radiotherapy only.
- 40% of patients receiving first-line treatment required second-line therapy.
- Two-year overall survival (OS) decreased significantly with each subsequent line of treatment (84% after 1st line to 36% after 4th line).
- The 10-year cumulative incidence of transformation was 13%.
Conclusions
- A significant proportion of follicular lymphoma patients can be managed with WaW, indicating its feasibility in clinical practice.
- Patients requiring multiple lines of therapy represent a group with substantial unmet clinical needs.
- These findings provide valuable real-world reference data for follicular lymphoma treatment and management strategies.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...